EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab

Yutaka Shimazu, Takuro Kameda, Toshio Kitawaki, Ayako Kamiunten, Masaaki Sekine, Hiroshi Kawano, Seiichi Sato, Kouichi Maeda, Takanori Toyama, Noriaki Kawano, Kiyoshi Yamashita, Masanori Takeuchi und 3 weitere

Clinical Immunology · 2026-01 · 282 · 110616

DOI: 10.1016/j.clim.2025.110616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2026-01. Verfasst von Yutaka Shimazu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Early Clinical Development, Kyoto University Hospital, Kyoto, Japan; Department of Hematology, Graduate School of Medicine, Kyoto Unive…. Hauptthemen laut MEDLINE: Leukemia-Lymphoma, Adult T-Cell, Antibodies, Monoclonal, Humanized, Monocytes, Lymphocytes. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mogamulizumab, an anti-CCR4 monoclonal antibody, is approved for relapsed/refractory (r/r) aggressive adult T-cell leukemia/lymphoma (ATL), although durable responses are limited. OBJECTIVE: To identify biomarkers associated with mogamulizumab efficacy, focusing on host immune status and known prognostic factors. METHODS: We retrospectively analyzed 315 patients with r/r aggressive ATL using real-world data from Japan. Clinical and prognostic variables were analyzed for association with overall survival (OS), stratified by mogamulizumab use. RESULTS: Among 315 patients, 97 received mogamulizumab (Moga [+]). One-year OS was higher in Moga (+) than Moga (-) patients (51.2 % vs. 34.0 %, p = 0.006). Multivariate analysis identified age < 70, PS 0-1, cCa < 11 mg/dL, albumin ≥3.5 g/dL, LDH < 265 IU/L, LMR ≥ 2.6, and Moga (+) use as independent predictors of OS. In Moga (+) patients, cCa and LMR remained independent prognostic factors. CONCLUSION: LMR is a novel prognostic factor in r/r ATL and may provide useful information when considering mogamulizumab-based treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia-Lymphoma, Adult T-CellAntibodies, Monoclonal, HumanizedMonocytesLymphocytesHumansMaleFemaleMiddle AgedAgedRetrospective StudiesPrognosisAdultAged, 80 and overYoung AdultRecurrence

Stichwörter der Autor:innen

Adult T-cell leukemia-lymphomalymphocyte/monocyte ratiomogamulizumabpredictive markers

Substanzen

mogamulizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Early Clinical Development, Kyoto University Hospital, Kyoto, Japan; Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Division of Hematology, Diabetes and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: kitawaki@kuhp.kyoto-u.ac.jp.
  • Koga General Hospital, Miyazaki, Japan.
  • Miyakonojo Medical Center, Miyakonojo, Japan.
  • Miyazaki Prefectural Nobeoka Hospital, Nobeoka, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Shimazu, Y., Kameda, T., Kitawaki, T., Kamiunten, A., Sekine, M., Kawano, H., Sato, S., Maeda, K., Toyama, T., Kawano, N., Yamashita, K., Takeuchi, M., Ishizaki, J., Shimoda, K., & Takaori-Kondo, A. (2026). Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab. Clinical Immunology, 282, 110616. https://doi.org/10.1016/j.clim.2025.110616

Vancouver

Shimazu Y, Kameda T, Kitawaki T, Kamiunten A, Sekine M, Kawano H, et al. Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab. Clinical Immunology. 2026;282:110616. doi:10.1016/j.clim.2025.110616

BibTeX
@article{Shimazu2026,
  author = {Shimazu, Yutaka and Kameda, Takuro and Kitawaki, Toshio and Kamiunten, Ayako and Sekine, Masaaki and Kawano, Hiroshi and Sato, Seiichi and Maeda, Kouichi and Toyama, Takanori and Kawano, Noriaki and Yamashita, Kiyoshi and Takeuchi, Masanori and Ishizaki, Junzo and Shimoda, Kazuya and Takaori-Kondo, Akifumi},
  title = {Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab},
  journal = {Clinical Immunology},
  year = {2026},
  volume = {282},
  pages = {110616},
  doi = {10.1016/j.clim.2025.110616}
}
Kostenlos starten →